Maraviroc · Selzentry / Celsentri

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: HIV

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (2)
CA
  • Celsentri (maraviroc) tablets 150 and 300 mg, CCR5-tropic HIV-1 (product monograph, holder ViiV Healthcare ULC; the Summary Basis of Decision gives the Notice of Compliance to Pfizer Canada as 2007-09-21)
Product first approved 2007pdf.hres.ca
EU
  • Celsentri: treatment-experienced adults, adolescents and children 2 years and older infected with CCR5-tropic HIV-1
Product first approved 2007EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (13)
HIV
NCT01896921 · University of Maryland, Baltimore
2013-09 – 2018-12 · HIV
What this study did
NCT03708861 · University of Turin, Italy
2016-01 – 2017-12 · HIV Infection
What this study did
NCT03178084 · Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
2014-10-15 – 2017-03-07 · HIV/AIDS
What this study did
NCT01348308 · ANRS, Emerging Infectious Diseases
2011-09 – 2016-03 · HIV-1 Infection, AIDS
What this study did
NCT00935480 · Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
2010-10 – 2014-08-08 · HIV Infections
What this study did
NCT00844519 · University of California, San Francisco
2010-01 – 2014-06 · HIV Infection, Cardiovascular Disease, Inflammation, HIV Infections
What this study did
NCT00537394 · National Institute of Allergy and Infectious Diseases (NIAID)
2008-01 – 2013-04 · HIV Infections
What this study did
NCT00478231 · ViiV Healthcare
2007-07 – 2010-09 · Acquired Immunodeficiency Syndrome, HIV Infection
What this study did
NCT00426660 · ViiV Healthcare
2007-02 – 2010-06 · HIV Infections
What this study did
NCT00719823 · ViiV Healthcare
2008-08 – 2010-05 · Human Immunodeficiency Virus Type 1
What this study did
Phase 2/3 (9)
HIV
NCT03129113 · University College, London
2017-03-01 – 2020-11-06 · Hepatic Steatosis, HIV-1-infection
What this study did
NCT02159027 · University of Hawaii
2015-06 – 2019-02 · AIDS Dementia Complex
What this study did
NCT01154673 · University of Toronto
2011-11 – 2014-09 · Acute HIV Infection
What this study did
NCT01060618 · Asociacion para el Estudio de las Enfermedades Infecciosas
2009-05 – 2011-12 · HIV Infections
What this study did
Other / comorbidity
NCT03172026 · University of California, Los Angeles
2019-08-01 – 2020-10-01 · Stroke
What this study did
Phase 2 (30)
HIV
NCT06805656 · Federal University of São Paulo
2026-07-15 – 2028-06-01 · Hiv, HIV I Infection
What this study did
NCT00791700 · ViiV Healthcare
2009-04-22 – 2023-06-30 · Human Immunodeficiency Virus
What this study did
NCT02741323 · National Institute of Allergy and Infectious Diseases (NIAID)
2017-01-01 – 2022-05-10 · HIV Infections, Kidney Diseases
What this study did
NCT01291459 · Association Pour la Recherche en Infectiologie
2011-09 – 2015-12 · HIV
What this study did
NCT01505114 · National Institute of Allergy and Infectious Diseases (NIAID)
2012-06 – 2015-11 · HIV Infection
What this study did
NCT01276236 · University of California, San Francisco
2011-03-09 – 2015-04-30 · Kaposi's Sarcoma
What this study did
NCT00795444 · Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
2008-03 – 2015-01 · HIV-1
What this study did
NCT01400412 · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
2012-01-17 – 2014-06-30 · HIV-1 Infection
What this study did
NCT00976404 · Robert L. Murphy
2009-11 – 2014-06 · HIV Infection
What this study did
NCT00987948 · University of Hawaii
2010-01 – 2013-08 · HIV Infections
What this study did
NCT01420523 · ANRS, Emerging Infectious Diseases
2011-12 – 2013-04 · Human Immunodeficiency Virus, Lipohypertrophy
What this study did
NCT00993148 · Northwestern University
2010-05 – 2013-04 · HIV-1 Infection, HIV Infections
What this study did
NCT00827112 · ViiV Healthcare
2009-03 – 2011-07 · Human Immunodeficiency Virus-1
What this study did
NCT00944541 · French National Agency for Research on AIDS and Viral Hepatitis
2009-09 – 2011-01 · HIV Infection, HIV Infections
What this study did
NCT00643643 · ViiV Healthcare
2002-10 – 2003-06 · HIV Infections
What this study did
Other / comorbidity
NCT06853223 · University of California, San Francisco
2025-12-07 – 2028-08-14 · Primary Graft Dysfunction, Lung Transplantation, Acute Lung Injury(ALI), Natural Killer Cell Mediated Immunity
What this study did
NCT07080567 · Emmanuel Carrera
2025-07-14 – 2027-12 · Ischemic Stroke, Stroke, Stroke Acute
What this study did
NCT06511063 · Icahn School of Medicine at Mount Sinai
2024-10-01 – 2026-12 · Long Covid
What this study did
NCT04789616 · University of Calgary
2022-09-15 – 2025-12 · Stroke
What this study did
NCT04966429 · Tel-Aviv Sourasky Medical Center
2021-05-01 – 2024-06 · Post Stroke Cognitive Impairment
What this study did
NCT05932550 · Tel-Aviv Sourasky Medical Center
2020-08-04 – 2022-08-04 · Post-stroke Depression
What this study did
NCT04475991 · Hospital General de México Dr. Eduardo Liceaga
2021-07-13 – 2022-03-25 · COVID-19
What this study did
NCT04710199 · Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
2021-02-23 – 2021-07-08 · Virus Diseases
What this study did
NCT04441385 · Hospital Universitario Infanta Leonor
2020-06-26 – 2021-02-08 · COVID-19
What this study did
NCT01785810 · Abramson Cancer Center at Penn Medicine
2013-02 – 2018-07-12 · Hematologic Malignancy
What this study did
NCT02208037 · National Heart, Lung, and Blood Institute (NHLBI)
2014-08 – 2017-10 · Acute Leukemia, Chronic Myelogenous Leukemia, Myelodysplasia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Lymphoma, B-Cell, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Hodgkin's Lymphoma
What this study did
NCT02799888 · Affiliated Hospital to Academy of Military Medical Sciences
2014-04 – 2017-04 · Graft-versus-host Disease, Hematopoietic Stem Cell Transplantation
What this study did
NCT00764465 · Garden State Infectious Disease Associates, PA
2008-10 – 2008-12 · Healthy
What this study did
NCT00427934 · Pfizer
2007-02 – 2008-10 · Arthritis, Rheumatoid
What this study did
Phase 1/2 (4)
HIV
NCT02475915 · SEARCH Research Foundation
2015-01 – 2016-03 · Acute HIV Infection
What this study did
Other / comorbidity
NCT02167451 · Children's Hospital Medical Center, Cincinnati
2014-07 – 2018-09 · Diagnoses That Require Stem Cell Transplant, Graft Versus Host Disease (GVHD)
What this study did
NCT00948753 · Abramson Cancer Center at Penn Medicine
2009-06 – 2011-04 · Graft-versus-host Disease, Hematopoietic Stem Cell Transplantation
What this study did
Phase 1 (32)
HIV
NCT03118661 · Washington University School of Medicine
2018-03-19 – 2025-09-30 · HIV-1-infection
What this study did
NCT02778204 · National Institute of Allergy and Infectious Diseases (NIAID)
2017-06-05 – 2019-11-20 · HIV Infections
What this study did
NCT02346084 · International Partnership for Microbicides, Inc.
2015-01 – 2016-03 · HIV/AIDS
What this study did
NCT02486510 · Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
2012-07 – 2015-12 · HIV-1 Infection
What this study did
NCT02480894 · ViiV Healthcare
2015-07-07 – 2015-09-21 · Infection, Human Immunodeficiency Virus
What this study did
NCT01749566 · Emory University
2012-12 – 2015-05 · HIV
What this study did
NCT01894776 · Ottawa Hospital Research Institute
2013-06 – 2015-02 · HIV Infection, HIV-1 Infection, Mycobacterium Avium Complex (MAC)
What this study did
NCT01719627 · Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
2012-10 – 2015-01 · HIV
What this study did
NCT02039323 · University of North Carolina, Chapel Hill
2014-02 – 2014-04 · Healthy Adult Females
What this study did
NCT01363037 · International Partnership for Microbicides, Inc.
2011-11 – 2012-08 · HIV Infections
What this study did
NCT01348763 · Imperial College London
2011-10 – 2012-05 · HIV
What this study did
NCT01597648 · GlaxoSmithKline
2011-11 – 2012-01 · Infection, Human Immunodeficiency Virus I
What this study did
NCT01242579 · International Partnership for Microbicides, Inc.
2011-01 – 2011-07 · HIV Infections
What this study did
NCT00703586 · Rockefeller University
2007-09 – 2011-05 · HIV Infections
What this study did
NCT00982878 · Imperial College London
2009-09 – 2011-02 · HIV Infections
What this study did
NCT01056874 · ViiV Healthcare
2010-03 – 2010-04 · Healthy, HIV Infections
What this study did
NCT00775294 · University of North Carolina, Chapel Hill
2008-05 – 2010-03 · HIV/AIDS
What this study did
NCT00821535 · ViiV Healthcare
2009-02 – 2009-05 · Human Immunodeficiency Virus (HIV) Infection
What this study did
NCT00771823 · St Stephens Aids Trust
2008-05 – 2008-11 · HIV Infections
What this study did
NCT00496782 · ViiV Healthcare
2007-07 – 2008-10 · HIV Infections
What this study did
Other / comorbidity
NCT04721301 · University Hospital Heidelberg
2017-01-15 – 2023-03-15 · Colorectal Cancer Metastatic, Pancreatic Cancer Metastatic
What this study did
NCT04435522 · Rhode Island Hospital
2020-10-01 – 2020-12-31 · COVID
What this study did
NCT03274804 · University Hospital Heidelberg
2018-04-01 – 2020-03-01 · Metastatic Colorectal Cancer, MSS
What this study did
NCT02625207 · ViiV Healthcare
2015-11-06 – 2016-03-26 · Healthy Subjects
What this study did
NCT01980329 · Johns Hopkins University
2013-01 – 2014-03 · Cytochrome P450 CYP3A5 Enzyme Polymorphism, Healthy Subjects, Pharmacokinetics of Maraviroc
What this study did
NCT01627717 · Centre hospitalier de l'Université de Montréal (CHUM)
2012-06 – 2014-02 · Healthy
What this study did
NCT01330199 · University of North Carolina, Chapel Hill
2012-02 – 2013-08 · Healthy Adult Females
What this study did
NCT01133210 · Washington University School of Medicine
2011-01 – 2012-11 · Hypertriglyceridemia
What this study did
NCT01597895 · ViiV Healthcare
2012-07 – 2012-08 · Healthy
What this study did
NCT01290211 · ViiV Healthcare
2011-04 – 2011-06 · Healthy
What this study did
NCT01140412 · ViiV Healthcare
2010-07 – 2010-10 · Healthy
What this study did
NCT00783484 · Pfizer
2008-10 – 2009-05 · Healthy Volunteers
What this study did
Phase 4 (35)
HIV
NCT04965662 · Guy's and St Thomas' NHS Foundation Trust
2018-01-01 – 2021-03-16 · HIV-1-infection
What this study did
NCT02519777 · National Institute of Allergy and Infectious Diseases (NIAID)
2016-04-21 – 2021-01-05 · HIV Infections
What this study did
NCT03163277 · Giovanni Di Perri
2017-05-15 – 2020-06-30 · Hiv, Neurocognitive Dysfunction
What this study did
NCT02990312 · University of Maryland, Baltimore
2017-05-01 – 2019-07-17 · Hiv, Kidney Transplant, HIV Reservoir, CCR5
What this study did
NCT02881762 · University of Maryland, Baltimore
2017-06-01 – 2019-03-27 · Hepatitis C, Human Immunodeficiency Virus
What this study did
NCT03218592 · University of North Carolina, Chapel Hill
2017-06-28 – 2018-12-07 · HIV/AIDS
What this study did
NCT03402815 · University Of Perugia
2015-01-01 – 2017-09-30 · HIV Infection With Other Conditions, Cardiovascular Risk Factor, Atherosclerosis, Inflammation
What this study did
NCT01637259 · Kirby Institute
2012-06 – 2015-12 · Proteinuria, HIV
What this study did
NCT01384682 · Kirby Institute
2011-08 – 2015-12 · HIV
What this study did
NCT01367236 · Imperial College London
2013-01 – 2015-10 · HIV, Impaired Cognition
What this study did
NCT01367210 · Catholic University of the Sacred Heart
2011-06 – 2015-06 · HIV Infection
What this study did
NCT00981318 · Rodwick, Barry M., M.D.
2009-12 – 2015-05 · HIV Infections, Acquired Immunodeficiency Syndrome
What this study did
NCT01327547 · ViiV Healthcare
2011-05-18 – 2015-03-24 · HIV Coinfection
What this study did
NCT01449006 · Bruce Brew
2011-10 – 2014-09 · Human Immunodeficiency Virus (HIV), HIV Associated Neurocognitive Disorders (HAND)
What this study did
NCT01866267 · St. Hope Foundation
2013-01 – 2014-06 · Human Immunodeficiency Virus, AIDS
What this study did
NCT00925756 · University of California, San Diego
2008-10-20 – 2014-04-11 · HIV Infections
What this study did
NCT01275625 · ViiV Healthcare
2011-06 – 2013-07 · HIV
What this study did
NCT00981773 · Imperial College London
2009-09 – 2013-03 · HIV Infections
What this study did
NCT00875368 · S.F.L. van Lelyveld
2009-02 – 2012-08 · HIV Infections
What this study did
NCT00966329 · Germans Trias i Pujol Hospital
2009-10 – 2012-05 · HIV, HIV Infections
What this study did
NCT01190293 · St Stephens Aids Trust
2010-01 – 2012-03 · HIV Infection
What this study did
NCT01049204 · St Stephens Aids Trust
2009-07 – 2011-06 · HIV Infections
What this study did
NCT00884858 · ASST Fatebenefratelli Sacco
2009-04 – 2011-04 · HIV Infections
What this study did
NCT01068873 · Temple University
2010-04 – 2010-12 · HIV Infections
What this study did
NCT01235013 · Hospital Clinic of Barcelona
— · HIV-1 Infection
What this study did
NCT00735072 · University of California, San Francisco
2008-09 – 2010-07 · HIV Infection
What this study did
NCT01013987 · Fundación Huésped
started 2010-02 · HIV-1 Adults Patients, AIDS, Triple Class Failure
What this study did
NCT00782301 · ViiV Healthcare
2009-03 – 2010-02 · Hepatitis B, Human Immunodeficiency Virus, Hepatitis C, Chronic
What this study did
NCT00717067 · ViiV Healthcare
2008-07 – 2008-11 · Human Immunodeficiency Virus (HIV) Infection
What this study did
Other / comorbidity
NCT07668505 · Chinese University of Hong Kong
2026-09-01 – 2029-08-31 · Myositis
What this study did
NCT01389063 · S.F.L. van Lelyveld
2012-01 – 2014-10 · Endothelial Dysfunction
What this study did
NCT00666705 · ViiV Healthcare
2008-02 – 2008-03 · Healthy
What this study did
Early phase / not applicable (8)
HIV
NCT02961829 · Federal University of São Paulo
2015-07 – 2020-03 · Chronic Infection, HIV
What this study did
NCT02333045 · Emory University
2015-01 – 2016-10-28 · HIV
What this study did
NCT02934022 · Southern California Institute for Research and Education
2012-06 – 2014-12 · HIV Infection
What this study did
NCT01204905 · University of Maryland, Baltimore
2010-09 – 2014-05-16 · HIV Infections
What this study did
NCT00525733 · Rockefeller University
2007-10 – 2013-12 · HIV Infections
What this study did
NCT00988780 · Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
2009-12 – 2013-04 · Immune Reconstitution Inflammatory Syndrome, HIV, HIV Infections
What this study did
NCT00709111 · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
2009-01 – 2010-04 · HIV Infections
What this study did
Other / comorbidity
NCT02134717 · Kevin F. Gibson
2014-01 – 2015-05 · Sarcoidosis
What this study did
Appears in other studies (2)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (1)
HIV
NCT01033760 · ANRS, Emerging Infectious Diseases
2010-04 – 2013-12 · HIV-1 Infections
What this study did
Phase 4 (1)
HIV
NCT00853840 · ViiV Healthcare
2008-04 – 2008-05 · AIDS
What this study did

Competitive landscape

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for HIV: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Maraviroc (Selzentry / Celsentri): this drugApprovedSmall moleculeCCR5 co-receptorPartial signal
NCT00098293: Percentage of Participants With Viral Load of Less Than 400 Copies/Milliliter [Copies/mL] and Less Than 50 Copies/mL of Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) at Week 48 for Full Analysis Set (FAS) Population (Week 48): Maraviroc Once Daily + CBV (DB), Then Twice Daily + CBV (OL) — Less than 400 copies/mL: 61.5%; Less than 50 copies/mL: 55.8% | Maraviroc Twice Daily + CBV (DB) — Less than 400 copies/mL: 70.6%; Less than 50 copies/mL: 65.3% vs Efavirenz Once Daily + CBV (DB) — Less than 400 copies/mL: 73.1%; Less than 50 copies/mL: 69.3%
Amprenavir
ApprovedUS marketing discontinued
Small moleculeHIV proteasenot yet gradedNo reviewed efficacy summary in this indication
Bictegravir (Biktarvy)ApprovedSmall moleculeHIV integraseReliable signal
NCT03110380: Participants with HIV-1 RNA ≥50 copies/mL at week 48 (FDA snapshot): 0.4% with B/F/TAF vs 1.1% with dolutegravir plus emtricitabine/tenofovir alafenamide; difference -0.7% (95% CI -2.8% to 1.0%), inside the pre-specified 4% non-inferiority margin (CT.gov posted analysis).
NCT02607956: Week 48 HIV-1 RNA <50 copies/mL: 89.4% B/F/TAF vs 92.9% DTG + F/TAF; difference -3.5 percentage points (95.002% CI -7.9 to 1.0); prespecified non-inferiority margin 12%.
Bictegravir / Lenacapavir (Bixlenvo)ApprovedSmall moleculeHIV integrase, HIV capsidPartial signal
NCT05502341: Phase 3 primary, HIV-1 RNA >=50 copies/mL at week 48 (FDA snapshot): BIC/LEN 0.8% (n=371) vs stable baseline regimen 1.1% (n=186), difference -0.3% (95.002% CI -2.3% to 1.8%); Gilead states the non-inferiority criterion was met. Phase 2 week 24: 0% and 1.9% vs 0% (CT.gov posted results).
Cabotegravir (Apretude)ApprovedSmall moleculeHIV integraseReliable signal
NCT02720094: Number of Participants With Documented Incident HIV Infections During Steps 1 and 2 (HIV tests at enrollment, weeks 2, 4, 5, every injection visit (every 8 weeks) and every safety visit (2 weeks after each injection visit). Analyzed through week 153 or the date of DSMB decision to unblind all participants, whichever is earliest.): Cabotegravir 13/2280 vs TDF/FTC 39/2281
Cabotegravir / Rilpivirine (Cabenuva)ApprovedSmall moleculeHIV integrase, HIV reverse transcriptaseWeak signal
NCT03299049: HIV-1 RNA >=50 copies/mL (FDA Snapshot) at Week 48, cabotegravir LA + rilpivirine LA every 8 weeks vs every 4 weeks: 1.7% vs 1.0%, adjusted difference 0.8% (95% CI -0.6 to 2.2); non-inferior against the 4% margin (CT.gov posted results).
NCT02938520: Virologic failure (HIV-1 RNA >=50 copies/mL, FDA Snapshot) at Week 48, cabotegravir LA + rilpivirine LA every 4 weeks vs abacavir/dolutegravir/lamivudine: 2.1% vs 2.5%, adjusted difference -0.4% (95% CI -2.8 to 2.1); non-inferior against the 6% margin (CT.gov posted results).
Darunavir (Prezista)ApprovedSmall moleculeHIV proteasePartial signal
NCT00110877: HIV RNA <400 copies/mL at Week 48 (per-protocol population): darunavir-ritonavir 77% (220/286) vs lopinavir-ritonavir 68% (199/293); estimated difference 9% (95% CI 2-16).
Dolutegravir (Tivicay / Triumeq / Dovato / Juluca (component))ApprovedSmall moleculeHIV integraseReliable signal
NCT01263015: Week 48 HIV-1 RNA <50 c/mL: 88% with dolutegravir plus abacavir/lamivudine vs 81% with Atripla; difference 7.3 percentage points (95% CI 2.3 to 12.2; p=0.003).
NCT01449929: Percentage of Participants With Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies/Milliliter (c/mL) at Week 48 (Week 48): DTG 50 mg QD 90% vs DRV 800 mg + RTV 100 mg QD 83%
Doravirine (Pifeltro)ApprovedSmall moleculeHIV reverse transcriptaseReliable signal
NCT02403674: Week 48 HIV-1 RNA <50 copies/mL: 84.3% doravirine/tenofovir/lamivudine vs 80.8% ATRIPLA; treatment difference 3.537 percentage points (95% CI -1.951 to 9.026), with a non-inferiority margin of -10. Tier-1 neuropsychiatric events: dizziness 8.8% vs 37.1% (difference -28.3, p<0.001); sleep disorders/disturbances 12.1% vs 25.5% (difference -13.5, p<0.001); altered sensorium 4.4% vs 8.2% (difference -3.8, p=0.033).
NCT02275780: Week 48 HIV-1 RNA <50 copies/mL: 83.8% doravirine vs 79.9% darunavir/ritonavir; treatment difference 3.913 percentage points (95% CI -1.590 to 9.415), non-inferiority margin -10 percentage points.
Doravirine / Islatravir (Idvynso)ApprovedSmall moleculeHIV reverse transcriptase, HIV-1 Reverse TranscriptasePartial signal
NCT05630755: HIV-1 RNA at or above 50 copies/mL at Week 48 (FDA Snapshot), switch to doravirine/islatravir (n=342) vs staying on bictegravir/emtricitabine/tenofovir alafenamide (n=171): 1.5% vs 0.6%; risk difference 0.88 percentage points (95% CI -1.86 to 2.90), non-inferiority p=0.003 against a 4-point margin (CT.gov posted results).
NCT04233879: Percentage of Participants With Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) <50 Copies/mL at Week 48 (Week 48): Group 1: DOR/ISL 88.9% vs Group 2: BIC/FTC/TAF 88.3%
Elvitegravir (Stribild)ApprovedSmall moleculeHIV integrasePartial signal
NCT01095796: The Percentage of Participants With Virologic Success Using the Food and Drug Administration (FDA)-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 Ribonucleic Acid (RNA) < 50 Copies/mL at Week 48 (Week 48): Stribild 87.6% vs Atripla 84.1%
Emtricitabine (Emtriva)ApprovedSmall moleculeHIV reverse transcriptasePartial signal
NCT00112047: Percentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 48 (Defined by the Food and Drug Administration [FDA] Time-to-Loss-of Virologic Response [TLOVR] Algorithm (48 weeks): EFV+FTC+TDF 84.4 Percentage of participants | CBV+EFV 72.8 Percentage of participants
Emtricitabine / Tenofovir Disoproxil Fumarate (Truvada)ApprovedSmall moleculeHIV reverse transcriptasePartial signal
NCT00323544: Primary endpoint, week 24 change from baseline in absolute hemoglobin: switching to Truvada+efavirenz vs continuing Combivir+efavirenz, mean difference +0.37 g/dL (95% CI 0.15 to 0.58 g/dL), P<0.001, favoring the switch arm.
Etravirine (Intelence)ApprovedSmall moleculeHIV reverse transcriptaseReliable signal
NCT00254046: Confirmed viral load <50 copies/mL at week 24: TMC125 (etravirine) 56% (170/304) vs placebo 39% (119/308); difference in response rates 17% (95% CI 9-25), p=0.005
NCT00255099: Confirmed viral load <50 copies/mL at Week 24 (intention to treat): etravirine (TMC125) 62% (183/295) vs placebo 44% (129/296); difference 18% (95% CI 11-26; p=0.0003).
Fostemsavir (Rukobia)ApprovedSmall moleculeHIV gp120Partial signal
NCT02362503: Mean Change in Logarithm to the Base 10 (log10) HIV-1 Ribonucleic Acid (RNA) From Day 1 at Day 8-Randomized Cohort (Day 1 and Day 8): Randomized Cohort-fostemsavir 600 mg BID -0.791 Log10 copies per milliliter (c/mL) (95% CI -0.885 to -0.698) vs Randomized Cohort-Placebo -0.166 Log10 copies per milliliter (c/mL) (95% CI -0.326 to -0.007)
NCT01384734: HIV-1 RNA < 50 copies/mL at Week 24: fostemsavir 400 mg BID 80% (95% CI 66.3 to 90), 800 mg BID 69% (54.6 to 81.7), 600 mg QD 76% (62.5 to 87.2) and 1200 mg QD 72% (57.5 to 83.8) vs the atazanavir/ritonavir reference arm 75% (60.4 to 85.7).
Ibalizumab (Trogarzo)ApprovedMonoclonal antibodyCD4 receptorWeak signal
NCT02475629: Efficacy: Proportion of Participants Achieving a Viral Load Reduction of at Least 0.5 Log 10: ITT-MEF (Day 14): Open-Label Ibalizumab Plus OBR 82.5% (95% CI 67.72% to 92.66%)
Lenacapavir (Sunlenca)ApprovedSmall moleculeHIV capsidPartial signal
NCT04150068: Percentage of Participants in Cohort 1 Achieving a Reduction of ≥ 0.5 log10 Copies/mL in Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) From Baseline to the End of Functional Monotherapy Period (Baseline up to Day 1 SC Visit (14 days after the first dose of oral lencapavir) or Day 15): Cohort 1A: Lenacapavir 87.5 percentage of participants | Cohort 1B: Placebo to Lenacapavir 16.7 percentage of participants
NCT04143594: Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) < 50 Copies/mL at Week 54 as Determined by the United States Food and Drug Administration (US FDA)-Defined Snapshot Algorithm (Week 54): Group 1: SC LEN+(F/TAF→ TAF) 90.4% vs Group 2: SC LEN + (F/TAF → BIC) 84.9% vs Group 3: Oral LEN + F/TAF 84.6% vs Group 4: B/F/TAF 92.0%; p=0.7178 (Group 1: SC LEN+(F/TAF→ TAF) vs Group 4: B/F/TAF), p=0.3900 (Group 2: SC LEN + (F/TAF → BIC) vs Group 4: B/F/TAF), p=0.3797 (Group 3: Oral LEN + F/TAF vs Group 4: B/F/TAF) missed
Lenacapavir (Yeztugo)ApprovedSmall moleculeHIV capsidReliable signal
NCT04925752: HIV incidence: 0.10 per 100 PY on twice-yearly lenacapavir (2 infections) vs background incidence 2.37 per 100 PY (IRR 0.04; 95% CI 0.01-0.18; P<0.001) and vs F/TDF 0.93 per 100 PY (IRR 0.11; 95% CI 0.02-0.51; P=0.002) (PURPOSE 2, NEJM 2025).
NCT04994509: HIV incidence: 0 infections in 2,134 on twice-yearly lenacapavir (0 per 100 PY; 95% CI 0.00-0.19) vs background incidence 2.41 per 100 PY (IRR 0.00; 95% CI 0.00-0.04; P<0.001) and vs F/TDF 1.69 per 100 PY (IRR 0.00; 95% CI 0.00-0.10; P<0.001) (PURPOSE 1, NEJM 2024).
Raltegravir (Isentress)ApprovedSmall moleculeHIV integraseReliable signal
NCT00293254: Percentage of Participants Achieving HIV RNA <400 Copies/mL at Week 16 (16 Weeks): Raltegravir 400 mg b.i.d. + OBT 77.3% (95% CI 71.3 to 82.6) vs Placebo + OBT 42.9% (95% CI 33.8 to 52.3)
NCT00293267: Percentage of Participants Achieving HIV RNA <400 Copies/mL at Week 16 (16 Weeks): Raltegravir 400 mg b.i.d. + OBT 77.7% (95% CI 71.8 to 82.9) vs Placebo + OBT 41% (95% CI 32 to 50.5)
Rilpivirine (Edurant)ApprovedSmall moleculeHIV reverse transcriptaseReliable signal
NCT00540449: Week 48 TLOVR virologic response: 287/346 rilpivirine vs 285/344 efavirenz; adjusted difference -0.4% (95% CI -5.9% to 5.2%), p<0.0001; non-inferiority margin -12%.
NCT00543725: Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], <50 Copies Per mL) at Week 48 (Week 48): TMC278 — Responder: 291/340; Virologic failure: 24/340; Death: 1/340; Discontinued due to AE: 8/340; Discontinued due to other reason than AE: 16/340 vs Efavirenz — Responder: 276/338; Virologic failure: 18/338; Death: 3/338; Discontinued due to AE: 21/338; Discontinued due to other reason than AE: 20/338
Somatropin (Serostim)ApprovedProtein / enzyme therapeuticGrowth hormone receptorPartial signal
NCT00082628: Change in visceral adipose tissue area at Week 12: -32.6 cm² Serostim (n=210) vs 0.5 cm² placebo (n=74), p<0.001. phase 3 result · pivotal pending
NCT01077960: Primary endpoint: mean change in trunk fat from baseline to week 12, -1.7 kg (SD 1.4; n=106; p<0.001). phase 3 result · pivotal pending
Tenofovir Alafenamide / Emtricitabine (Descovy)ApprovedSmall moleculeHIV reverse transcriptaseReliable signal
NCT02842086: Incidence of HIV-1 Infection Per 100 Person Years (PY) (When all participants completed minimum follow-up of 48 weeks and at least 50% of the participants completed 96 weeks of follow-up after randomization or permanently discontinued from the study (maximum 125 weeks)): Descovy (DVY) 0.16 HIV-1 infections per 100 PY (95% CI 0.064 to 0.33) | Truvada (TVD) 0.342 HIV-1 infections per 100 PY (95% CI 0.191 to 0.564)
Tenofovir Disoproxil Fumarate (Viread)ApprovedSmall moleculeHIV reverse transcriptase (RT)Partial signal
NCT00528957: Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 48 (48 weeks): Tenofovir DF 83.3 percentage of participants | Stavudine or Zidovudine 91.8 percentage of participants | All TDF 85.4 percentage of participants missed
NCT00352053: Time-weighted Average Change From Baseline Through Week 24 (DAVG24) in Plasma HIV-1 RNA (Baseline to 24 Weeks): Tenofovir DF -1.58 log10 copies/mL (IQR -2.15 to -0.27) | Placebo -1.549 log10 copies/mL (IQR -2.36 to -0.34) missed
Tesamorelin (Egrifta WR)ApprovedPeptideGrowth hormone-releasing hormone (GHRH) receptorPartial signal
NCT00608023: Changes From Baseline in Fasting Blood Glucose at Week 52 (Baseline and Week 52): Tesamorelin 52 Weeks 0 mg/dL (Standard Deviation 16) missed
Tipranavir (Aptivus)ApprovedSmall moleculeHIV proteasePartial signal
NCT00144170: Treatment Response at Week 48 (after 48 weeks of treatment): Tipranavir(TPV)/Low Dose Ritonavir(r) 34.5% vs Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r) 15%
NCT00054717: Treatment Response at Week 48 (At week 48): Tipranavir(TPV)/Low Dose Ritonavir(r) 33.8% vs Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r) 16.2%
ACC017Phase 3Small moleculeHIV integrasePartial signal
NCT06719310: The mean decrease in the groups ranged from 1.44 to 2.34 log 10 copies/mL and none of the participants experienced viral breakthrough. A total of 86.11% of the participants had HIV-RNA of less than 50 copies/mL at day 29.
Albuvirtide (Aikening)Phase 3PeptideHIV gp41Partial signal
NCT02369965: Primary, HIV-1 RNA <50 copies/mL at week 48 (mITT, interim analysis with 46 albuvirtide and 50 control patients at week 48): 80.4% (37/46) albuvirtide + lopinavir/ritonavir vs 66.0% (33/50) NRTIs + lopinavir/ritonavir; difference 14.4% (95% CI -3.0% to 31.9%) against a prespecified non-inferiority margin of -12%, met.
AlimatravirPhase 3Small moleculeHIV-1 Reverse TranscriptaseWeak signal
NCT06045507: Primary outcomes, safety (no formal efficacy test): participants with at least one adverse event 62/101 (3 mg), 69/101 (6 mg) and 66/99 (12 mg) monthly MK-8527 vs 31 on placebo; discontinuation due to an adverse event 0, 2 and 1 vs 2 (CT.gov posted results).
Azvudine (FNC)Phase 3Small moleculeHIV reverse transcriptasePartial signal
NCT04109183: 符合方案集(PPS)阿兹夫定 2 mg 组、阿兹夫定 3 mg 组、阿兹夫定 4 mg 组和 3TC 组结果分别为 97.2%、100%、100% 和 97.5%。经卡方分析各组之间无显著统计学差异(P>0.05)
Dapivirine (Dapivirine Vaginal Ring)Phase 3Small moleculeHIV reverse transcriptaseReliable signal
NCT01617096: HIV-1 seroconversion: 71/1313 dapivirine vs 97/1313 placebo; incidence 27% lower with dapivirine (95% CI 1 to 46; P = 0.046), 37% lower after exclusion of two low-adherence sites (P = 0.007).
IslatravirPhase 3Small moleculeHIV-1 Reverse Transcriptasenot yet gradedNo reviewed efficacy summary in this indication
Islatravir / LenacapavirPhase 3Small moleculeHIV-1 Reverse Transcriptase, HIV capsidnot yet gradedNo reviewed efficacy summary in this indication
SemzuvolimabPhase 3Monoclonal antibodyCD4 receptorWeak signalNo reviewed efficacy summary in this indication
TeropavimabPhase 3Monoclonal antibodyHIV envelopenot yet gradedNo reviewed efficacy summary in this indication
ZinlirvimabPhase 3Monoclonal antibodyHIV envelopenot yet gradedNo reviewed efficacy summary in this indication
Elsulfavirine (Elpida)Phase 2/3Small moleculeHIV reverse transcriptasePartial signalNo reviewed efficacy summary in this indication
LeronlimabPhase 2/3Monoclonal antibodyCCR5 co-receptorWeak signal
NCT02483078: Proportion of Participants With ≥ 0.5 log10 Reduction in HIV-1 RNA Viral Load From Baseline at the End of the 1-week Double-blind Treatment Period (From baseline visit to week 1 visit): PRO 140 — With >= 0.5 LOG10 IN HIV-1 RNA VIRAL Load Change from Baseline: 64%; Without >= 0.5 LOG10 IN HIV-1 RNA VIRAL Load Change from Baseline: 36% | Placebo — With >= 0.5 LOG10 IN HIV-1 RNA VIRAL Load Change from Baseline: 23%; Without >= 0.5 LOG10 IN HIV-1 RNA VIRAL Load Change from Baseline: 77%
NCT02859961: Proportion of Participants Who Remain on PRO 140 Monotherapy Regimen at the End of Week 48 Without Experiencing Virologic Failure (From T1 (first treatment administration) to week 48 (T48).): Part 1 - 350 mg Weekly Injections of PRO 140, Group A 23% | Part 1 - 525 mg Weekly Injections of PRO 140, Group B 43% | Part 1 - 700 mg Weekly Injections of PRO 140, Group C 45%
UlonivirinePhase 2/3Small moleculeHIV reverse transcriptaseWeak signalFeatured results are safety only in this race
10-1074Phase 2Monoclonal antibodyHIV envelopeWeak signalFeatured results are safety only in this race
3BNC117Phase 2Monoclonal antibodyHIV envelopePartial signal
NCT03041012: Co-primary 1, plasma HIV-1 RNA decay rate, ART+romidepsin+3BNC117 vs ART only: daily decay 16.9% (95% CI -27.3% to -4.93%) vs 10.0% (95% CI -14.9% to -4.86%) from day 10 to 24 (P=0.048); comparable from day 0 to 10 and day 24 to 90, met. Co-primary 2, change in intact HIV-1 provirus frequency from baseline to day 365: all groups decreased, with no significant differences between the groups, missed.
CL-197Phase 2Small moleculeHIV reverse transcriptaseWeak signalNo reviewed efficacy summary in this indication
DezecapavirPhase 2Small moleculeHIV capsidPartial signal
NCT06039579: Monotherapy, VH4011499: Maximum Change From Baseline (Day 1) in Plasma HIV-1 RNA log10 (From Baseline (Day 1) and up to Day 11): Part 1b: VH4011499 Dose Level 1 — Baseline (Day 1): 5.001 log10 c/mL (Standard Deviation 0.7304); Maximum change compared to Baseline (Day 1): -1.834 log10 c/mL (Standard Deviation 0.5141) | Part 1b: VH4011499 Dose Level 2 — Baseline (Day 1): 4.339 log10 c/mL (Standard Deviation 0.6185); Maximum change compared to Baseline (Day 1): -1.797 log10 c/mL (Standard Deviation 0.4544) | Part 2b: VH4011499 Pre-specified Dose — Baseline (Day 1): 4.96 log10 c/mL (Standard Deviation 0.7288); Maximum change compared to Baseline (Day 1): -2.165 log10 c/mL (Standard Deviation 0.431) vs Matching Placebo for VH4011499 — Baseline (Day 1): 4.714 log10 c/mL (Standard Deviation 0.7736); Maximum change compared to Baseline (Day 1): -0.176 log10 c/mL (Standard Deviation 0.1969)
EnvafolimabPhase 2Monoclonal antibodyPD-L1Weak signalNo reviewed efficacy summary in this indication
HTI Vaccine (ChAdOx1.HTI / MVA.HTI)Phase 2VaccineHIV-1 conserved epitopes (HTI)Partial signal
NCT03204617: Primary, safety (grade 3 or 4 local and systemic reactions; no formal efficacy test): adverse events were mostly mild and transient, with no related serious adverse events. Secondary: HTI vaccines induced strong, broad CD4 and CD8 T-cell responses; all participants had detectable viral rebound during treatment interruption.
LipovirtidePhase 2PeptideHIV gp41Partial signalNo reviewed efficacy summary in this indication
LotivibartPhase 2Monoclonal antibodyHIV envelopeWeak signal
NCT04871113: Maximum Decline From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) Levels - Monotherapy Phase (Baseline (Day 1) and up to Day 84 or end of Monotherapy Phase): Part 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV) — Baseline (Day 1): 12258.5 Copies per milliliter (copies/mL) (range 1351 to 173710); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -12014.5 Copies per milliliter (copies/mL) (range -171577 to -1312) | Part 1: GSK3810109A 280 mg IV — Baseline (Day 1): 30833 Copies per milliliter (copies/mL) (range 5938 to 104585); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -26826.5 Copies per milliliter (copies/mL) (range -103583 to -5899) | Part 2: GSK3810109A 700 mg IV — Baseline (Day 1): 25466 Copies per milliliter (copies/mL) (range 7180 to 110387); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -25966 Copies per milliliter (copies/mL) (range -107218 to -6944) | Part 2: GSK3810109A 70 mg IV — Baseline (Day 1): 25689.5 Copies per milliliter (copies/mL) (range 7225 to 683576); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -14720.5 Copies per milliliter (copies/mL) (range -197793 to -4382) | Part 2: GSK3810109A 700 mg Subcutaneously (SC) — Baseline (Day 1): 23146 Copies per milliliter (copies/mL) (range 131 to 181078); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -12584 Copies per milliliter (copies/mL) (range -178423 to -69)
TMB-365 / TMB-380Phase 2CombinationCD4; HIV envelopenot yet gradedNo reviewed efficacy summary in this indication
TrosunilimabPhase 2Monoclonal antibodyα4β7 integrinPartial signalFeatured results are safety only in this race
VesatolimodPhase 2Small moleculeToll-like receptor 7 (TLR7) (agonist)Weak signalFeatured results are safety only in this race
VH4004280 (VH-280)Phase 2Small moleculeHIV capsidPartial signal
NCT06039579: Monotherapy, VH4004280: Maximum Change From Baseline (Day 1) in Plasma HIV-1 Ribonucleic Acid (RNA) log10 (From Baseline (Day 1) and up to Day 11): Part 1a: VH4004280 Dose Level 1 — Baseline (Day 1): 5.004 log10 c/mL (Standard Deviation 0.4592); Maximum change compared to Baseline (Day 1): -1.056 log10 c/mL (Standard Deviation 0.4567) | Part 1a: VH4004280 Dose Level 2 — Baseline (Day 1): 4.923 log10 c/mL (Standard Deviation 0.5428); Maximum change compared to Baseline (Day 1): -1.391 log10 c/mL (Standard Deviation 0.6986) | Part 2a: VH4004280 Pre-specified Dose — Baseline (Day 1): 4.866 log10 c/mL (Standard Deviation 0.7696); Maximum change compared to Baseline (Day 1): -1.983 log10 c/mL (Standard Deviation 0.2171) vs Matching Placebo for VH4004280 — Baseline (Day 1): 4.636 log10 c/mL (Standard Deviation 0.6641); Maximum change compared to Baseline (Day 1): -0.07 log10 c/mL (Standard Deviation 0.0574)
VH4524184Phase 2Small moleculeHIV integrasePartial signal
NCT06214052: Monotherapy: Maximum Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) (At Day 10): VH4524184 Dose 1 -1.17 Copies per milliliter (copies/mL) (Standard Deviation 0.46) | VH4524184 Dose 2 -2.15 Copies per milliliter (copies/mL) (Standard Deviation 0.254) | VH4524184 Dose 3 -2.31 Copies per milliliter (copies/mL) (Standard Deviation 0.463) vs Placebo -0.28 Copies per milliliter (copies/mL) (Standard Deviation 0.37)
JL18008Phase 1/2Protein / enzyme therapeuticIL-7 receptorWeak signalNo reviewed efficacy summary in this indication
LP-98Phase 1/2PeptideHIV gp41Partial signalNo reviewed efficacy summary in this indication
AGT103-TPhase 1Gene therapy / editingHIV proviral reservoir / autologous T cellsWeak signalFeatured results are safety only in this race
AinuovirinePhase 1Small moleculeHIV reverse transcriptaseWeak signalFeatured results are safety only in this race
AV000103A (ICVAX)Phase 1VaccineHIV antigensWeak signalFeatured results are safety only in this race
BNT168Phase 1VaccineHIV antigensnot yet gradedNo reviewed efficacy summary in this indication
BNT351Phase 1Monoclonal antibodyHIV envelopenot yet gradedNo reviewed efficacy summary in this indication
CPT31Phase 1PeptideHIV gp41Weak signalFeatured results are safety only in this race
MGD014Phase 1Multispecific antibodyHIV envelope gp120 x CD3Weak signalFeatured results are safety only in this race
MGD020Phase 1Multispecific antibodyHIV envelope gp41 x CD3Weak signalFeatured results are safety only in this race
MK-4646Phase 1Small molecule—Weak signalNo reviewed efficacy summary in this indication

Large race: only the 61 furthest-along competitors are listed; 7 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Compare side by side

Upcoming events

(7 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Selzentry / Celsentri (Maraviroc) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
November 2026 (1)
Phase 2Long CovidRecruiting
Est. primary completion 2026-11 · NCT06511063 · CT.gov ↗
What to watch
December 2026 (1)
Phase 2/3Long COVIDNot yet recruiting
Est. primary completion 2026-12-01 · NCT06974084 · CT.gov ↗
What to watch
2027 (3)
March 2027 (1)
Phase 2HIVRecruiting
Est. primary completion 2027-03-01 · NCT06805656 · CT.gov ↗
What to watch
July 2027 (1)
Phase 1/2HIVRecruiting
Est. primary completion 2027-07-30 · NCT05470491 · CT.gov ↗
What to watch
December 2027 (1)
Phase 2Ischemic Stroke, Stroke, Stroke AcuteRecruiting
Est. primary completion 2027-12 · NCT07080567 · CT.gov ↗
What to watch
2028 (1)
April 2028 (1)
Phase 2Primary Graft Dysfunction, Lung Transplantation, Acute Lung Injury(ALI), Natural Killer Cell Mediated ImmunityRecruiting
Est. primary completion 2028-04-01 · NCT06853223 · CT.gov ↗
What to watch
2029 (1)
August 2029 (1)
Phase 4MyositisNot yet recruiting
Est. primary completion 2029-08-31 · NCT07668505 · CT.gov ↗
What to watch

See the full readout calendar ↗